In Advance Of HSV-2 Vaccine Trials, Genocea Taps Investors For $35 Million
This article was originally published in The Pink Sheet Daily
The four-year-old antigen discovery platform developer has added corporate VCs, seeking to broaden its eventual exit opportunities.
You may also be interested in...
The vaccine developer tapped investors for a third round of financing as its lead programs begin clinical trials.
Hepatitis C, HIV, Antibiotics And Vaccines Headline Infectious Diseases Discussion At TAP Conference
In developing the infectious diseases track for this year’s Therapeutic Area Partnerships conference, planners focused on areas of unmet medical need, market potential, companies with a diversity of indications, strong science and multi-level partnering opportunities.
Advisory committee might closely scrutinize the requested indication for the 13-valent pneumococcal conjugate vaccine for adults age 50 and up; it is now indicated for children under six years old.